

Pergamon Tetrahedron Letters 41 (2000) 8897–8901

First total synthesis of mueggelone

Ken Ishigami, Hajime Motoyoshi and Takeshi Kitahara*

Department of Applied Biological Chemistry, *Graduate School of Agricultural and Life Sciences*, *The University of Tokyo*, 1-1-1 *Yayoi*, *Bunkyo*-*ku*, *Tokyo* 113-8657, *Japan*

Received 27 June 2000; revised 21 July 2000; accepted 24 July 2000

Abstract

All the four possible stereoisomers of mueggelone, an inhibitor of fish development, were efficiently synthesized in a stereoselective manner starting from D-arabinose, and the absolute configuration was determined to be 9*R*,12*S*,13*S*. © 2000 Elsevier Science Ltd. All rights reserved.

Keywords: asymmetric synthesis; reduction; lactonisation; epoxides.

Mueggelone (1) , which has a 10-membered lactone and epoxide, was isolated¹ from a bloom-foaming strain of *Aphanizomenon flos*-*aquae* in 1997 (Scheme 1). With mueggelone at a concentration of 10 μ g/mL, zebra fish larvae showed 45% mortality and the surviving larvae showed edema in the heart region and thrombosis. This compound is thought to play an ecologically important role in inhibition of the development of herbivorous fish. The stereochemistry of epoxide was proposed to be *trans* by spectroscopic analysis; however, the relative, as well as the absolute configuration of the three stereocenters remained unknown. Therefore, we undertook the synthesis of all the four possible stereoisomers of mueggelone (**1**, *ent*-**1**, **2**, *ent*-**2**) to determine the absolute configuration and to provide samples for further biological

Scheme 1.

* Corresponding author. Fax: +81-3-5841-8019; e-mail: atkita@mail.ecc.u-tokyo.ac.jp

⁰⁰⁴⁰⁻⁴⁰³⁹/00/\$ - see front matter © 2000 Elsevier Science Ltd. All rights reserved. PII: S0040-4039(00)01285-5

assay. Our synthetic strategy is illustrated in Scheme 1. We decided to utilize the key intermediate **A**, which could be transformed into any of the four stereoisomers via asymmetric reduction of ketone, macrolactonization and, finally, epoxide formation. Compound **A** was constructed by the Horner–Wadsworth–Emmons (HWE) reaction of the side chain part **B** with the lactone part **C**. Aldehyde **B** and phosphonate **C** was derived from commercially available compounds, D-arabinose and azelaic acid dimethyl ester, respectively.

The synthesis of the side chain part is outlined in Scheme 2. D-Arabinose was converted into alcohol **3** according to the known procedure.2 Protection of the hydroxyl group, followed by dethioacetalization with mercury salt gave an aldehyde, which was submitted to the Wittig reaction to afford *Z*-olefin **4**. The best ratio ($E/Z = 1:10$) was provided by using NaHMDS as a base, and the isomers were easily separated by silica gel column chromatography. The *Z*-olefin **4** was transformed into the corresponding primary alcohol in four steps, which was then mildly oxidized³ to give the desired aldehyde 6 .

Scheme 2.

Phosphonate **7** (prepared from azelaic acid dimethyl ester, dimethyl methylphosphonate, *n*-BuLi, THF, −78°C, 22%) was subjected to the HWE reaction with the aldehyde **6** (Scheme 3). Under the condition using *n*-BuLi as a base, the *E*/*Z* ratio was 96:4; however, partial epimerization (25%) of the TBSO group was observed. On the other hand, the procedure employing DBU-LiCl⁴ resulted in very little epimerization $(1-2\%)$ with excellent E/Z selectivity $(E/Z = > 99:1)$. In the next step, we tried several conditions for the asymmetric reduction of enone **8**, and the best selectivity was obtained with the CBS-reagent⁵ and borane–THF complex. The resultant two isomers and other undesired isomers (10*Z* isomer, TBSO epimer) were cleanly separated by preparative HPLC and the stereochemistry of each isomer was confirmed by the modified Mosher's method (Table 1).⁶ The difference in chemical shifts ensured the stereochem-

8898

Scheme 3.

Table 1 ¹⁴C NMR (300 MHz, CDCl₃) data for (*S*)- and (*R*)-MTPA ester of the (9*S*) derivative

o^MTPA PMBO 13 .CO ₂ Me 10 8 2 OTBS (9S)-derivative + MTPA								
Position		$\delta_S \negthinspace\negthinspace\negthinspace \delta_R$						
	(S) -MTPA	(R) -MTPA						
2	2.28	2.29	-0.01					
8	1.63	1.64	-0.01					
10	5.68	5.60	0.08					
11	5.94	5.83	0.11					
12	4.14	4.12	0.02					
13	3.32	3.30	0.02					

istry. Hydrolysis with LiOH furnished pure hydroxycarboxylic acid **9**a/b, respectively. Lactonization of 9α was successfully achieved by Yamaguchi's method⁷ to provide 10α in satisfactory yield (Scheme 4), together with a small amount of a dimeric lactone (5–10%). On the other hand, the Corey–Mukaiyama method⁸ was found to give only several unassignable compounds. Removal of the PMB group with DDQ proceeded without complication. In the following epoxide formation stage, we thought that the stereochemistry of the epoxide could be controlled by the direction of elimination. Initially, we decided to synthesize the (12*R*,13*R*) isomer such as **2**. Mesylation of alcohol **11**a, followed by treatment with TBAF provided the

Scheme 4.

Carbon	Natural	$1/ent-1$	$2/ent-2$	Carbon	Natural	$1/ent-1$	$2/ent-2$
1	173.5	173.4	173.4	10	132.8	132.7	132.8
2	35.1	35.0	35.1	11	128.6	128.5	129.1
3	29.9	29.8	29.9	12	57.4	57.4	57.3
$\overline{4}$	27.1	27.0	27.0	13	59.9	59.9	59.9
5	24.2	24.1	24.2	14	29.6	29.5	29.5
6	23.7	23.6	23.6	15	122.3	122.2	122.2
7	23.4	23.3	23.4	16	135.0	134.9	134.9
8	20.7	20.7	20.7	17	20.7	20.7	20.7
9	74.9	74.8	75.1	18	14.2	14.2	14.2

Table 2 ¹³C NMR (75.5 MHz, CDCl₃) data for natural mueggelone, $1/ent$ -1, and $2/ent$ -2

desired epoxylactone **2** in good yield. Next, we tried to obtain the (12*S*,13*S*) isomer in a similar manner. So, allylic mesylate **13**a was prepared from **10**a; however, it readily decomposed under the conditions of PMB deprotection. Therefore, we had to change the PMB group for another protecting group. Masking the hydroxyl group of **11**a with TBDPSCl was followed by selective removal of the TBS group with HF/acetonitrile to give the corresponding alcohol **12**a. It was mesylated and then treated with TBAF without purification to furnish **1**. Also, *ent***-1** and *ent***-2** were synthesized in the same way from **9**b.

With the four stereoisomers in hand, we carefully analyzed the NMR spectra and specific rotations. As for the ¹ H NMR, there was little difference between **1**/*ent*-**1** and **2**/*ent*-**2** to distinguish them. However, in the ^{13}C NMR spectra (Table 2), an obvious difference was observed at the C-11 position (natural: 128.6 ppm, **1**/*ent*-**1**: 128.5 ppm, **2**/*ent*-**2**: 129.1 ppm), which suggested **1**/*ent*-**1** should be the reasonable natural isomer. In addition, the value of specific rotation (natural: +28.3, synthetic **1**: +28.7, synthetic *ent*-**1**: −28.2) showed that **1** must be the natural product, i.e. mueggelone has the absolute configuration¹⁰ of $9R,12S,13S$. At first we referred this to the absolute configuration of malyngic acid,⁹ analogous to 1; nevertheless, the stereochemistry at C-9 was found to be the opposite.

In conclusion, we have completed the first synthesis of mueggelone (and its stereoisomers), in 2.1% overall yield from D-arabinose, and determined the absolute configuration of mueggelone to be 9*R*,12*S*,13*S*. Work is under way to refine every step of the synthesis, and to submit these isomers to further biological assay. Results will be reported in a full account.

Acknowledgements

The authors sincerely thank Professor Gabriele M. König, University of Bonn, for a kind gift of the spectral charts of natural mueggelone.

References

- 1. Papendorf, O.; Ko¨nig, G. M.; Wright, A. D.; Chorus, I.; Oberemm, A. *J*. *Nat*. *Prod*. **1997**, 60, 1298–1300.
- 2. Wong, M. Y. H.; Gray, G. R. *J*. *Am*. *Chem*. *Soc*. **1978**, 100, 3548–3553.
- 3. (a) Dess, D. B.; Martin, J. C. *J*. *Am*. *Chem*. *Soc*. **1991**, 113, 7277–7287. (b) Ireland, R. E.; Liu, L. *J*. *Org*. *Chem*. **1993**, 58, 2899.
- 4. Blanchette, M. A.; Choy, W.; Davis, J. T.; Essenfeld, A. P.; Masamune, S.; Roush, W. R.; Sakai, T. *Tetrahedron Lett*. **1984**, 25, 2183–2186.
- 5. (a) Corey, E. J.; Bakshi, R. K.; Shibata, S. *J*. *Am*. *Chem*. *Soc*. **1987**, 109, 5551–5553. (b) Corey, E. J.; Helal, C. J. *Angew*. *Chem*. *Int*. *Ed*. **1998**, 37, 1986–2012.
- 6. (a) Dale, J. A.; Mosher, H. S. *J*. *Am*. *Chem*. *Soc*. **1973**, 95, 512–519. (b) Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J*. *Am*. *Chem*. *Soc*. **1991**, 113, 4092–4096.
- 7. (a) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull*. *Chem*. *Soc*. *Jpn*. **1979**, 52, 1989–1993. (b) Mulzer, J.; Mareski, P. A.; Buschmann, J.; Luger, P. *Synthesis* **1992**, 215–228.
- 8. (a) Corey E. J.; Nicolaou, K. C. *J*. *Am*. *Chem*. *Soc*. **1974**, 96, 5614–5616. (b) Gerlach, H.; Thalmann, A. *Helv*. *Chim*. *Acta* **1974**, ⁵⁷, 2661–2663.
- 9. Malyngic acid is analogous to mueggelone, see: Cardellina II, J. H.; Moore, R. E. *Tetrahedron* **1980**, 36, 993–996.

10. Spectral data of synthetic **1**. IR (film): *ν* 2930, 1730, 1470, 1240 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ (ppm) 0.98 (3H, t, *J*=7.5 Hz, H-18), 1.05–1.80 (11H, m, Ha-3, H-4, H-5, H-6, H-7, H-8), 1.95–2.15 (3H, m, Hb-3, H-17), 2.20 (1H, m, Ha-2), 2.37 (2H, m, H-14), 2.53 (1H, ddd, *J*=2.7, 6.2, 15.2 Hz, Hb-2), 2.88 (1H, dt, *J*=2.2, 5.2 Hz, H-13), 3.16 (1H, dm, *J*=7.5 Hz, H-12), 5.25–5.60 (4H, m, H-9, H-11, H-15, H-16), 5.95 (1H, dd, *J*=5.1, 15.6 Hz, H-10); ¹³C NMR (75.5 MHz, CDCl₃): δ (ppm) 14.2, 20.7, 20.7, 23.3, 23.6, 24.1, 27.0, 29.5, 29.8, 35.0, 57.4, 59.9, 74.8, 122.2, 128.5, 132.7, 134.9, 173.4.